ライフサイエンスコーパス: parenteral administration

1 ltiple sclerosis and rheumatoid arthritis by parenteral administration.

2 duce recombinant pharmaceutical proteins for parenteral administration.

3 alf-life, necessitating frequent, continuous parenteral administration.

4 ific drug delivery and medical imaging after parenteral administration.

5 ut until recently it has required cumbersome parenteral administration.

6 al conditions that require frequent, chronic parenteral administration.

7 FpEF, but its use is limited by the need for parenteral administration.

8 us oocytes and were convulsant in mice after parenteral administration.

9 f less than 100nm are excellently suited for parenteral administration.

10 a Molina tree has been proved to be safe for parenteral administration and represents a potential alt

11 ncerns about its cost, the need for frequent parenteral administration, and the development of anti-E

12 qualitatively similar to that induced by VLP parenteral administration, and this response was enhance

13 sible particles in formulations intended for parenteral administration are of concern in the biopharm

14 ral drugs (ARVs) were recently developed for parenteral administration at monthly or longer intervals

15 more polar molecules that currently require parenteral administration because the vaginal epithelium

16 rising fewer injections and oral rather than parenteral administration, compared with a reference tre

17 The definition of resistance for parenteral administration does not apply to inhaled tobr

18 h oral administration and always <50 nM with parenteral administration, even when corresponding ascor

19 As an alternative to repetitive parenteral administration, gene therapy may provide a no

20 sc versus po also underscores the idea that parenteral administration is a reasonable alternative to

21 for patients, since repetitive and long-term parenteral administration is required as most proteins a

22 Parenteral administration of 2.2 g/kg glucose solution i

23 cumulation in cells is the topical, oral, or parenteral administration of 5-aminolevulinic acid, a pr

24 In a streptomycin-treated mouse model, parenteral administration of 5C12 significantly protecte

25 Parenteral administration of 6-OHDA to mice resulted in

26 Parenteral administration of a mouse anti-human CD8 mono

27 Topical and parenteral administration of an IgA monoclonal antibody

28 We used parenteral administration of antalarmin, a novel, small

29 teractions in tumors and normal tissue after parenteral administration of antitumor antibodies to hum

30 extracellular fluid was detected only after parenteral administration of ascorbate and when Asc(*-)

31 Parenteral administration of CD3-specific monoclonal ant

32 elling than reported selection in vivo after parenteral administration of ceftiofur.

33 Parenteral administration of CRH, however, results in hy

34 Parenteral administration of either native or recombinan

35 Neutralization of macaque IL-15 by parenteral administration of Hu714MuXHu reduces (>95%) c

36 Parenteral administration of IL-4 resulted in augmented

37 We have compared mucosal versus traditional parenteral administration of inactivated influenza vacci

38 Parenteral administration of iron produced increased iro

39 on absorption by activation of HIF-2alpha or parenteral administration of iron-dextran in HIF-2alpha

40 Parenteral administration of lipopolysaccharide 2-24 hou

41 Parenteral administration of lipopolysaccharide resulted

42 Finally, parenteral administration of MBL increased resistance of

43 its immunogenicity and also that mucosal or parenteral administration of microspheric formulations o

44 miliar arena or high light, familiar arena), parenteral administration of nicotine had bimodal action

45 Parenteral administration of platelet glycoprotein IIb/I

46 in all subjects, these results of the first parenteral administration of rAAV demonstrate that admin

47 Parenteral administration of recombinant human erythropo

48 een postulated as a potential alternative to parenteral administration of recombinant proteins.

49 Although parenteral administration of sufficient RSV-specific IgG

50 Here we show that long-term parenteral administration of superphysiological doses of

51 Collectively, these findings indicate that parenteral administration of the antioxidant ALA signifi

52 ioavailability issues related to the desired parenteral administration of the chosen clinical candida

53 ency disease (SCID) mice were transfected by parenteral administration of the vector.

54 In rats, parenteral administration of the water-soluble glipizide

55 ease may be transmitted by oral ingestion or parenteral administration of these conformationally alte

56 ated from blood rapidly via the stools after parenteral administration of thiomersal in vaccines.

57 Parenteral administration schedules have been evaluated

58 Furthermore, after parenteral administration, the FhHDM-1 peptide interacte

59 whereas liposomal AMB is costly and requires parenteral administration, thus development of novel for

60 with the following different adjuvants after parenteral administration to mice: alum, a derivative of

61 ohol-maintained responding after central and parenteral administrations, together with its low-effica